The pace of "innovation + internationalization" is accelerating, and many innovative pharmaceutical companies have achieved impressive results in the "mid-term exam".

Recently, Hengrui Medicine released its semi-annual report for 2025, with the company achieving record high revenue, net profit, and net cash flow from operating activities in the first half of the year. In the first half of the year, sales and licensing revenue for innovative drugs reached 9.561 billion yuan, accounting for 60.66% of the company's operating income, with sales revenue from innovative drugs reaching 7.57 billion yuan. Journalists have found that several companies, such as BeiGene and Johnson & Johnson Pharmaceutical, have disclosed their performance in the first half of the year, with the revenue from innovative drugs, progress in R&D pipelines, and overseas expansion plans becoming the focus of market attention. Industry insiders have stated that Chinese companies in the field of innovative drugs have moved from quantitative to qualitative changes, gradually shifting from "followers" to "leaders". The outlook for the innovative drug sector is expected to continue to be positive, with the pace of "innovation + internationalization" accelerating, becoming the core direction of the pharmaceutical sector.